About this Research Topic
This Research Topic is the first part of the article collection series: Molecular mechanisms and innovative therapeutic strategies for frontotemporal lobar degeneration, Volume II.
Frontotemporal lobar degeneration (FTLD) is one of the most common cause of earlyonset dementia. FTLD onset is characterized by progressive changes in behavior, personality and language; as disease progresses cognitive symptoms appear.FTLD is a clinically, pathologically and genetically heterogeneous disorder. Histopathological heterogeneity includes intraneuronal inclusions, mostly positive for tau or ubiquitin, with frequent cases of TDP-43 positivity, and more rarely FUS reactivity. About 30% of FTLD patients are familial with an autosomal dominant pattern of transmission. Mutations in a number of genes are associated with FTLD, most commonly in MAPT or GRN, and C90RF72 genes, and more rarely in VCP, TARDBP or FUS. A pathological classification of FTLD was developed according to the presence of protein aggregates, namely FTLD-Tau, FTLD-TDP43, FTLD-FUS, FTLD-UBS. There is some degree of correlation between the clinical type and pathological findings and this correlation is important for effective and selective intervention. There is no effective treatment for FTLD and due to its prevalence hard, innovative and interdisciplinary research is mandatory. Moreover, specific biomarkers aimed to monitor disease onset and progression and/or therapy efficacy are to be searched, also considering innovative approaches .The cognitive and behavioral impairments associated with FTLD interfere with successful engagement in daily life, such as parenting, working, and interpersonal relationships. There are currently only very limited medications for the management of the cognitive-behavioral symptoms, but non-pharmacological interventions may offer significant benefits to the quality of life of the diagnosed individual (neurorehabilitation, community-based services to help successful re-engagement in life activities and promote improved quality of life).
At molecular level, FTLD couples neurodegeneration and protein aggregation, and the basis of the pathogenic process are to be elucidated, also proposing a pivotal change of the point of view of the underlining degenerative pathways (for instance, by searching for soluble but toxic forms of the aggregation-prone proteins, in analogy to AD).
The therapeutic challenge implies many innovative approaches to be considered, for instance novel nanotechnology and biomaterial-based strategies to deliver drugs or therapeutic proteins to the brain, also in vivo, cell-based therapies (including stem cells) and DNA/RNA in vivo delivery.
This Research Topic aims at collecting contributions summarizing the state-of-the art in molecular, genetic and therapeutic aspects of FTLD, with a focus on original data suggesting novel pathogenic hypothesis and multidisciplinary therapeutic approaches, both pharmacological or not.
Frontotemporal lobar degeneration (FTLD) is one of the most common cause of earlyonset dementia. FTLD onset is characterized by progressive changes in behavior, personality and language; as disease progresses cognitive symptoms appear.FTLD is a clinically, pathologically and genetically heterogeneous disorder. Histopathological heterogeneity includes intraneuronal inclusions, mostly positive for tau or ubiquitin, with frequent cases of TDP-43 positivity, and more rarely FUS reactivity. About 30% of FTLD patients are familial with an autosomal dominant pattern of transmission. Mutations in a number of genes are associated with FTLD, most commonly in MAPT or GRN, and C90RF72 genes, and more rarely in VCP, TARDBP or FUS. A pathological classification of FTLD was developed according to the presence of protein aggregates, namely FTLD-Tau, FTLD-TDP43, FTLD-FUS, FTLD-UBS. There is some degree of correlation between the clinical type and pathological findings and this correlation is important for effective and selective intervention. There is no effective treatment for FTLD and due to its prevalence hard, innovative and interdisciplinary research is mandatory. Moreover, specific biomarkers aimed to monitor disease onset and progression and/or therapy efficacy are to be searched, also considering innovative approaches .The cognitive and behavioral impairments associated with FTLD interfere with successful engagement in daily life, such as parenting, working, and interpersonal relationships. There are currently only very limited medications for the management of the cognitive-behavioral symptoms, but non-pharmacological interventions may offer significant benefits to the quality of life of the diagnosed individual (neurorehabilitation, community-based services to help successful re-engagement in life activities and promote improved quality of life).
At molecular level, FTLD couples neurodegeneration and protein aggregation, and the basis of the pathogenic process are to be elucidated, also proposing a pivotal change of the point of view of the underlining degenerative pathways (for instance, by searching for soluble but toxic forms of the aggregation-prone proteins, in analogy to AD).
The therapeutic challenge implies many innovative approaches to be considered, for instance novel nanotechnology and biomaterial-based strategies to deliver drugs or therapeutic proteins to the brain, also in vivo, cell-based therapies (including stem cells) and DNA/RNA in vivo delivery.
This Research Topic aims at collecting contributions summarizing the state-of-the art in molecular, genetic and therapeutic aspects of FTLD, with a focus on original data suggesting novel pathogenic hypothesis and multidisciplinary therapeutic approaches, both pharmacological or not.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
